Clinical Trials Browser

Phase 1 × Neoplasm Metastasis × Nivolumab × Clear all

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT04514484 2026-03-18

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

8 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04840589 2026-03-18

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Phase 1 Recruiting

25 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

57 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02408861 2026-01-21

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Terminated

79 enrolled 24 charts

GastrointestinalSarcomaThoracic

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

Clinical Trials

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

NYM

NEBULA

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

REGONIVO

NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

SPICE

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)